Search Results 311-320 of 16295 for nivolumab
To investigate the efficacy of autologous Epstein-barr virus (EBV)-specific T cells for the treatment of EBV positive Diffuse Large B Cell Lymphoma (DLBCL), ...
TG4010 is a suspension of recombinant Modified Vaccinia virus strain Ankara (MVA strain) carrying coding sequences for human MUC1 antigen and human interleukin- ...
Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Bevacizumab blocks the ability of tumors to grow new blood vessels and ...
6 months to 5 years post-treatment, as well as those in disease remission who are being treated with immunotherapies like Nivolumab. Exclusion Criteria ...
The purpose of this study is to develop a novel immunotherapeutic strategy to treat Recurrent Respiratory Papillomatosis (RRP) patients and cure the disease. A ...
There is evidence that colonic inflammation plays a major role in colon polyp and colorectal cancer development. For example, inflammatory bowel disease is a ...
... nivolumab, pembrolizumab, atezolizumab, OX40 agonists, 4-1BB agonists). Toxicities due to prior therapy must be stable and recovered to Grade ≤ 1 (except ...
Romidepsin and lenalidomide may stop the growth of cancer cells by blocking enzymes needed for cell growth. Giving rituximab together with romidepsin and ...
In-home Versus In-Clinic Subcutaneous Nivolumab Administration through Connected and Remote Cancer CARE Beyond Walls. Jacksonville, Fla. The purpose of this ...
BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an ...
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
The challenge ends 10/10. Your gift today can have 5X the impact on AI research and technology.